{"nctId":"NCT00946998","briefTitle":"Chronic Kidney Disease Antidepressant Sertraline Trial","startDateStruct":{"date":"2010-02-08","type":"ACTUAL"},"conditions":["Chronic Kidney Disease","Depression"],"count":201,"armGroups":[{"label":"Sertraline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sertraline"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Sertraline","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female adults aged greater than 21 years.\n* Predialysis stages 3, 4 or 5 CKD.\n* Current Major Depressive Episode.\n* QID-C-16 score of 11.\n* Able to understand and sign informed consent.\n\nExclusion Criteria:\n\n* No healthcare power of attorney to sign informed consent.\n* Unwilling or unable to participate.\n* Kidney transplant recipient.\n* Initiated on maintenance dialysis\n* Significant hepatic dysfunction or liver enzyme abnormalities 3 times the upper limits of normal.\n* Terminal chronic obstructive pulmonary disease or cancer.\n* Recent history of active bleeding, such as gastrointestinal bleeding requiring hospitalization 3 months prior\n* Current use of class I anti-arrhythmic medications.\n* Use of pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine or methyldopa; tri-cyclic anti-depressants, neuroleptics or anti-convulsants, excluding gabapentin\n* Use of other serotonergic drugs or supplements such as triptans, tramadol, linezolid, tryptophan, and St. John's Wort.\n* Ongoing use of anti-depressants\n* Past treatment failure on Sertraline\n* Initiation of psychotherapy for depression in the 3 months prior to study entry\n* Alcohol or substance abuse or dependence that requires acute detoxification at study entry\n* Present or past psychosis or Bipolar I or II disorder\n* Dementia or a Mini-Mental State Examination score of \\<23\n* Suicidal ideation\n* Pregnancy, lactation and women of childbearing potential not using adequate contraception","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Exit in Depression Symptom Severity as Measured by the QIDS-C-16 Score.","description":"The score range is 0 to 27; higher scores indicate more severe depression; a score of 0 to 5 corresponds to a normal affect; 6 to 10 to a mild affect; 11 to 15 to a moderate affect; 16 to 20 to a severe affect; and 21 or greater to very severe depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":null},{"groupId":"OG001","value":"-4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Response to Treatment Defined as a Decline of 50% in the Baseline QIDS-C-16 Score and Remission of Depression Defined as a QIDS-C-16 Score of 5","description":"The score range is 0 to 27; higher scores indicate more severe depression; a score of 0 to 5 corresponds to a normal affect; 6 to 10 to a mild affect; 11 to 15 to a moderate affect; 16 to 20 to a severe affect; and 21 or greater to very severe depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Exit in Overall Function as Assessed by the Work and Social Adjustment Scale","description":"Each item is rated on a 0 to 8 Likert scale with 0 indicating no impairment and 8 indicating severe impairment and a total score range of 0 to 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":null},{"groupId":"OG001","value":"-3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life From Baseline to Exit in the Kidney Disease Quality of Life -Short Form, Version 1.3, Patient-reported Overall Health.","description":"Raw scores from version 1.3 were transformed to a scale from 0 to 100, in which higher numbers signify more favorable quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Events During the 12 Week Study Duration.","description":"death, dialysis initiation, hospitalizations, or bleeding requiring transfusion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":97},"commonTop":["Nausea, indigestion, or vomiting","Insomnia","Diarrhea","Somnolence","Dizziness, syncope, or fall"]}}}